We are live on ! Find out more
DERM icon

Journey Medical

56 hedge funds and large institutions have $46.6M invested in Journey Medical in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

56% more capital invested

Capital invested by funds: $30M → $46.6M (+$16.7M)

47% more funds holding

Funds holding: 3856 (+18)

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

7.84% more ownership

Funds ownership: 29.71%37.55% (+7.8%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
56
Holders Change
+18
Holders Change %
+47.37%
% of All Funds
0.74%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
25
Increased
14
Reduced
11
Closed
7
Calls
Puts
Net Calls
Net Calls Change

DERM Hedge Fund Activity: Q2 2025 in Review

56 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q2 2025, worth a combined $46.6M — up 56% from $30M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new DERM positions and 7 closed out — a net gain of 18 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $3.39M. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $1.99M sold.

  • 56 institutional investors held Journey Medical (DERM) as of Q2 2025, up from 38 in Q1 2025.
  • Funds reported $46.6M of Journey Medical stock for Q2 2025, up 56% quarter-over-quarter.
  • 25 funds opened new Journey Medical positions in Q2 2025 and 7 closed out, a net change of +18 holders.
  • The largest Journey Medical buyer in Q2 2025 was BlackRock, an estimated $3.39M added.
  • The largest Journey Medical seller in Q2 2025 was Cambridge Investment Research Advisors, an estimated $1.99M sold.

Based on aggregated 13F filings for Q2 2025.